scholarly journals Cerebrospinal Fluid Human Immunodeficiency Virus Type 1 (HIV‐1) Suppression and Efavirenz Drug Concentrations in HIV‐1–Infected Patients Receiving Combination Therapy

1999 ◽  
Vol 180 (3) ◽  
pp. 862-864 ◽  
Author(s):  
K. T. Tashima ◽  
A. M. Caliendo ◽  
M. Ahmad ◽  
J. M. Gormley ◽  
W. D. Fiske ◽  
...  
1998 ◽  
Vol 3 (2) ◽  
pp. 97-102
Author(s):  
Rebekah JA Gass ◽  
Dave Shugarts ◽  
Russell Young ◽  
Michael Allen ◽  
Mary Rosandich ◽  
...  

Susceptibility to zidovudine and lamivudine was determined on human immunodeficiency virus type 1 (HIV-1) isolates obtained from patients who added lamivudine after 6 months of treatment with zidovudine. Lamivudine-resistant isolates that were also zidovudine-resistant were recovered from 13/16 (81%) patients after 6 months of dual therapy. In contrast to findings in anti-retroviral therapy-naive patients, these results suggest that dual resistance to zidovudine and lamivudine emerges relatively quickly when lamivudine is added to zidovudine as a single agent in the majority of patients with extensive prior zidovudine treatment.


2000 ◽  
Vol 38 (12) ◽  
pp. 4637-4639 ◽  
Author(s):  
Yi-Wei Tang ◽  
Joe T.-J. Huong ◽  
Robert M. Lloyd ◽  
Paul Spearman ◽  
David W. Haas

The source of human immunodeficiency virus type 1 (HIV-1) RNA in cerebrospinal fluid (CSF) during HIV-1 infection is uncertain. The sequence heterogeneity of HIV-1 RNA in simultaneous CSF and plasma samples was characterized for five patients at the baseline and during the first week of antiretroviral therapy by two commercial genotyping methodologies. In individual subjects, the sequences in CSF samples differed significantly from those in plasma. In contrast, the viral sequences in CSF at the baseline did not differ from the sequences in CSF during treatment. Similarly, viral sequences in plasma did not vary over this interval. This study provides evidence that HIV-1 RNA in CSF and plasma arise from distinct compartments.


1991 ◽  
Vol 32 (3) ◽  
pp. 259-268 ◽  
Author(s):  
Luigi M.E. Grimaldi ◽  
Antonella Castagna ◽  
Davide Maimone ◽  
Gian Vito Martino ◽  
Alberto Dolci ◽  
...  

2000 ◽  
Vol 74 (18) ◽  
pp. 8524-8531 ◽  
Author(s):  
Fabrizio Mammano ◽  
Virginie Trouplin ◽  
Veronique Zennou ◽  
Francois Clavel

ABSTRACT Human immunodeficiency virus type 1 (HIV-1) resistance to protease inhibitors (PI) is a major obstacle to the full success of combined antiretroviral therapy. High-level resistance to these compounds is the consequence of stepwise accumulation of amino acid substitutions in the HIV-1 protease (PR), following pathways that usually differ from one inhibitor to another. The selective advantage conferred by resistance mutations may depend upon several parameters: the impact of the mutation on virus infectivity in the presence or absence of drug, the nature of the drug, and its local concentration. Because drug concentrations in vivo are subject to extensive variation over time and display a markedly uneven tissue distribution, the parameters of selection for HIV-1 resistance to PI in treated patients are complex and poorly understood. In this study, we have reconstructed a large series of HIV-1 mutants that carry single or combined mutations in the PR, retracing the accumulation pathways observed in ritonavir-, indinavir-, and saquinavir-treated patients. We have then measured the phenotypic resistance and the drug-free infectivity of these mutant viruses. A deeper insight into the evolutionary value of HIV-1 PR mutants came from a novel assay system designed to measure the replicative advantage of mutant viruses as a function of drug concentration. By tracing the resultant fitness profiles, we determined the range of drug concentrations for which mutant viruses displayed a replicative advantage over the wild type and the extent of this advantage. Fitness profiles were fully consistent with the order of accumulation of resistance mutations observed in treated patients and further emphasise the key importance of local drug concentration in the patterns of selection of drug-resistant HIV-1 mutants.


1999 ◽  
Vol 37 (12) ◽  
pp. 4099-4106 ◽  
Author(s):  
Nouara Yahi ◽  
Catherine Tamalet ◽  
Christian Tourrès ◽  
Natacha Tivoli ◽  
Franck Ariasi ◽  
...  

The aim of the present study was to evaluate the resistance-associated mutations in 302 human immunodeficiency virus type 1 (HIV-1)-infected patients receiving combination therapy and monitored in Marseille, France, hospitals from January 1997 to June 1998. In the reverse transcriptase (RT) gene, the most frequent mutations were found at codons 215 (53%), 41 (34%), and 67, 70, 184, and 210 (>20%). One deletion and two insertions in the β3-β4 hairpin loop of the finger subdomain (codon 69) were detected. Interesting associations and/or exclusions of specific mutations were observed. In 96% of RT genes, a mutation at codon 70 (most frequently, K70R) was associated with a wild-type genotype at position 210 (P < 10−5). Similarly, a mutation at codon 210 (most frequently, L210W) was generally associated with mutations at codons 41 (92%) and 215 (96%) but not at codon 219 (16%) or codon 70 (4%) (P < 10−5). In the protease gene, the most prevalent mutations were at codons 63 (84%), followed by codons 10, 36, 71, 77, and 93 (ca. 20%). As for RT, pairwise associations of mutations were observed. Analysis of the mutation patterns for patients with undetectable HIV-1 loads revealed a high proportion (65%) of wild-type RT genotypes but only 18% wild-type protease genotypes. For patients with high viral loads (>100,000 copies/ml), more than 50% of the RT and protease genes displayed three or more mutations. The significant correlation between the level of viremia in plasma and the number of resistance mutations in the protease (P = 0.007) and RT (P = 0.00078) genes strengthens the importance of defining the genotype of the predominant HIV-1 quasispecies before initiating antiretroviral therapy.


1994 ◽  
Vol 36 (1) ◽  
pp. 32-39 ◽  
Author(s):  
W. Royal ◽  
O. A. Selnes ◽  
M. Concha ◽  
T. E. Nance-Sproson ◽  
J. C. McArthur

2000 ◽  
Vol 44 (5) ◽  
pp. 1397-1403 ◽  
Author(s):  
R. Renae Speck ◽  
Charles Flexner ◽  
Chun-Juan Tian ◽  
Xiao-Fang Yu

ABSTRACT Human immunodeficiency virus type 1 (HIV-1) produces two polyproteins, Pr55Gag and Pr160Gag-Pol, that are cleaved into mature functional subunits by the virally encoded protease. Drugs that inhibit this protease are an important part of anti-HIV therapy. We studied the ordered accumulation of Gag and Gag-Pol processing intermediates by variably blocking the protease with HIV-1 protease inhibitors (PIs). Variable protease inhibition caused accumulation of a complex pattern of processing intermediates, which was the same after incubating HIV-1-infected cells with increasing concentrations of either one of the peptidomimetic inhibitors indinavir, saquinavir (SQV), ritonavir (RTV), nelfinavir, and SC-52151 or one of the nonpeptidomimetic inhibitors DMP450, DMP323, PNU-140135, and PNU-109112 for 3 days. The patterns of Gag and Gag-Pol processing intermediate accumulation were nearly identical when the following were compared: cell- versus virion-associated proteins, HIV-1-infected transformed cell lines versus primary human peripheral blood mononuclear cells (PBMCs) and HIV-1MN versus HIV-1IIIB virus strains. RTV was a more potent inhibitor of p24 production in PBMCs than SQV by approximately 7-fold, whereas SQV was a more potent inhibitor in transformed cells than RTV by approximately 30-fold. Although the antiretroviral potency of HIV-1 PIs may change as a function of cell type, the polyprotein intermediates that accumulate with increasing drug concentrations are the same. These results support sequential processing of Gag and Gag-Pol polyproteins by the HIV-1 protease and may have important implications for understanding common cross-resistance pathways.


Sign in / Sign up

Export Citation Format

Share Document